$Aethlon Medical(AEMD.US)$ The best time to buy shares, sell at 1.00, everyone ~ 😃 There is good news, but the sharp decline was only brief

$Plug Power(PLUG.US)$ today 6.00🚀

$Novavax(NVAX.US)$
May 13, 2024
GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.

$Novavax(NVAX.US)$ 🚀 Target price: 180.00 🚀 As a long-term holder, I'm sure one day will come!

$Novavax(NVAX.US)$
As the KP.2 variant spreads rapidly in the United States, Novavax's JN.1 vaccine demonstrates effective neutralizing responses, proving its capability to adapt to viral evolutions. The vaccine has received WHO endorsement and is scheduled for distribution in the U.S. this fall, pending FDA approval. These developments highlight Novavax's strategic presence ...

$Novavax(NVAX.US)$
In 2024, Novavax's development reached a new climax, and the company's stock price and business development showed impressive performance. From a $1.2 billion vaccine license agreement with Sanofi to plans to promote its JN.1 protein-based non-mRNA COVID-19 vaccine globally, Novavax has certainly taken a place in the global biotech industry. In this context, many investors may be asking: is Novavax's stock still worth buying at the current price of $8-10?
Strong market dynamics
Novavax not only soared more than 99% in the first quarter of 2024, but also announced strong financial results. All of this further strengthened the market's confidence in its business model after the company reached a major vaccine licensing agreement with Sanofi. This type of collaboration provides a continuous revenue stream, while also showing Novavax's competitiveness and brand influence in the global vaccine market.
Innovative vaccine development
Additionally, the World Health Organization (WHO) recommended Novavax's JN.1 COVID-19 vaccine, which not only recognized its technology and product effectiveness, but also opened the door to the upcoming fall vaccine market. According to the company's latest non-clinical data, JN...

$Novavax(NVAX.US)$ still can buy right?????🙏🏻?

$Novavax(NVAX.US)$
1. The results of the collaboration between royalties and Sanofi:
Novavax senior management said it is expected that the milestones reached through royalties and the partnership with Sanofi will exceed the value the company may generate through its own efforts. The statement highlights the key role of collaboration and licensing strategies in driving the company's growth.
2. The transformation from an innovator to a commercial enterprise:
Company executives pointed out that Novavax's transformation from an innovation-driven company to a fully commercialized enterprise has always faced challenges. This shift places high demands on the company's strategy and operating model.
3. US Covid vaccine distribution plan:
Novavax plans to vaccinate against Covid at distribution centers in the US no later than mid-August. This shows that the company is actively promoting the distribution and accessibility of its vaccines.
4. Fall Vaccine Preparation and Regulatory Approvals:
The executive also said the company plans to prepare the Covid vaccine for fall in early September and is awaiting approval from the US Food and Drug Administration. This step is critical to ensure that the vaccine is marketed in a timely manner.
5. Improvement of retail channels:
Novavax's Covid vaccine will improve retail channels this season, which means the company is increasing market coverage and consumer engagement for its products, according to executives.
Analytical Short Essay: Why Investors Should...